Also Read: Regeneron’s Dupixent COPD Sales To Reach $20B By 2026, Analyst Sees Larger Addressable Market The condition ...

Citi initiated coverage of Regeneron (REGN) with a Neutral rating and $895 price target Multiple clinical data readouts should “keep ...

Oral presentation shares head-to-head results for investigational combination pozelimab plus cemdisiran vs. ravulizumab in paroxysmal nocturnal ...

Regeneron should weather the Eylea biosimilar launch storm and continue to deliver long-term shareholder value. See why REGN ...

Regeneron released a strong financial report for Q3 and was the 15th of 16 in the last four years. Read why I upgrade REGN ...

Despite disappointing third-quarter results for Regeneron’s high-dose Eylea injection, analysts continued to be cautiously ...

Shares of Regeneron Pharmaceuticals Inc. REGN inched 0.07% higher to $829.43 Tuesday, on what proved to be an all-around ...

The safety results from the EoE KIDS study were consistent with the known safety profile of Dupixent in adolescents and ...

Oppenheimer lowered the firm’s price target on Regeneron (REGN) to $1,000 from $1,150 and keeps an Outperform rating on the ...

Regeneron Pharmaceuticals (NASDAQ:REGN – Get Free Report) had its target price decreased by Royal Bank of Canada from ...

On Thursday, Regeneron Pharmaceuticals Inc (NASDAQ:REGN) reported third-quarter adjusted EPS of $12.46, up 8% year-over-year, ...

Sanofi and Regeneron’s Dupixent (dupilumab) has been approved by the European Commission (EC) to treat eosinophilic ...